Strategic Consulting, Elevated

Matthew is a seasoned professional with a diverse background encompassing project, portfolio, and operations management in the pharmaceutical and healthcare industries. His career highlights include leadership positions at top-tier organizations like Pfizer, Merck, and CSL, where he successfully led initiatives in drug development, resource management, and portfolio delivery. With a Ph.D. in Organic Chemistry from Stanford and an MHSA (dual MBA/MPH) from the University of Michigan, Ann Arbor, Matthew brings a unique blend of scientific expertise and business acumen to his roles.

Known for his strategic vision and ability to bridge the gap between science and business leveraging both generative and agentic AI, he has a track record of driving transformative change and enhancing operational efficiencies. His experience in stakeholder management and end-to-end drug development combined with technical expertise make him a valuable asset in driving organizational growth, productivity and innovation.

Some roles over the past decade that highlight strategic capabilities include:

·       Interim Head of the R&D PMO for Agentic AI (Confidential top 10 pharma client, current engagement)

·       Head of Resource and Capacity Management, Global R&D (CSL)

·       Head of Preclinical and Early Clinical Portfolio Management (BioCelerate)

·       Lead IT Client Services Representative, Preclinical R&D (Merck)

·       Numerous niche consulting engagements as Program Leader (3+ Pharma/Biotech)

Links of interest:

·       A representative book: Applications of Transition Metal Catalysis in Drug Discovery and Development | Wiley Online Books

·       An expert opinion I authored: https://www.tandfonline.com/doi/full/10.1517/13543776.2010.496777

·       A representative granted patent:  CA2736880A1 - 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors - Google Patents

·       My linkedin page: Matthew L. Crawley, PhD, MHSA, PMP | LinkedIn